AI firm Lunit plans to partner with Daiichi Sankyo on AI-driven biomarker and translational oncology research.
Under the collaboration, Daiichi Sankyo will make use of Lunit's SCOPE uIHC for quantitative immunohistochemical analysis and SCOPE IO for immune phenotyping and spatial analysis to develop novel biomarkers, Lunit said.



















